Reporting Likelihood Ratio in Autoimmune Serology: Just a Theory or Feasible in Practice?
Clinical Chemistry · 02.03.2024 · 70 (3) · 482-485
DOI: 10.1093/clinchem/hvad222 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 01.02.2024. Verfasst von Xavier Bossuyt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Correct interpretation of autoimmune serology test results is complex. A dichotomous interpretation (positive test result indicates disease and negative test result indicates absence of disease) is an oversimplification. A probabilistic approach is more authentic: a positive test result increases the probability of disease, whereas a negative test result decreases the probability of disease. The post-test probability of disease depends on the pre-test probability (i.e., probability of disease without knowledge of test result) and the test performance characteristics (sensitivity and specificity) (1). Generally, we have difficulties in correctly estimating the probability of disease based on the test result and performance characteristics of the test. Usually, we tend to overrate the probability of disease in the presence of a positive test result (2). Interpretation of autoimmune serology should take into account that for many autoantibodies the probability of disease increases with increasing antibody level. Such a relationship between autoantibody level and probability of disease is increasingly recognized, for example, by international organizations such as ESPGHAN (European Society for Pediatric Gastroenterology, Hepatology and Nutrition) and EULAR/ACR (European Alliance of Associations for Rheumatology/American College of Rheumatology). The ESPGHAN guidelines for diagnosis of celiac disease in children state that a biopsy can be avoided if IgA anti-tissue transglutaminase antibodies exceed 10 times the upper limit of normal (3). The 2010 EULAR/ACR classification criteria for rheumatoid arthritis assign a higher weight to rheumatoid factor (RF) and anti-citrullinated protein antibody (ACPA) levels that exceed 3 times the upper limit of normal than to RF and ACPA levels that are between the upper limit of normal and 3 times the upper limit of normal (4). Although many clinicians and laboratory professionals, as well as international organizations, appreciate that the probability of disease increases with increasing antibody level, such information is generally not included in reports by clinical laboratories. Therefore, there is a need to quantify and communicate how strongly a laboratory test result is associated with presence/absence of disease.
Autor:innen und Institutionen
- Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
- Department of Microbiology, Immunology and Transplantation, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium.
- Laboratory Medicine, OLV Hospital, Aalst, Belgium.
Zitieren
APA
Bossuyt, X., & Van Hoovels, L. (2024). Reporting Likelihood Ratio in Autoimmune Serology: Just a Theory or Feasible in Practice?. Clinical Chemistry, 70(3), 482-485. https://doi.org/10.1093/clinchem/hvad222
Vancouver
Bossuyt X, Van Hoovels L. Reporting Likelihood Ratio in Autoimmune Serology: Just a Theory or Feasible in Practice?. Clinical Chemistry. 2024;70(3):482-485. doi:10.1093/clinchem/hvad222
BibTeX
@article{Bossuyt2024,
author = {Bossuyt, Xavier and Van Hoovels, Lieve},
title = {Reporting Likelihood Ratio in Autoimmune Serology: Just a Theory or Feasible in Practice?},
journal = {Clinical Chemistry},
year = {2024},
volume = {70},
number = {3},
pages = {482--485},
doi = {10.1093/clinchem/hvad222}
}
EUVIMED